INTRODUCTION {#sec0005}
============

Radical cystectomy (RC) with pelvic lymph node dissection (PLND) has long represented the gold standard of treatment in patients with muscle-invasive bladder cancer (MIBC). RC and PLND allows for potentially definitive local oncologic control, and its utilization is supported by a large body of evidence \[[@ref001]\]. Nevertheless, RC is associated with substantial morbidity, as 30-day complication and mortality rates can range from 31--51% and 1.5--2.7%, respectively \[[@ref003]\]. As such, bladder preservation strategies are often employed as an alternative treatmentoption.

Bladder preserving approaches are generally utilized in two very different subsets of patients: a) those deemed medically unfit due to comorbidities or opting against RC with PLND, and b) those meeting strict criteria for curative intent. These criteria include urothelial histology, cT2 disease, complete transurethral resection of bladder tumor (TURBT) with no visible tumor remaining, and lack of hydronephrosis \[[@ref006]\]. Single modality bladder preservation techniques, including isolated TURBT, radiotherapy (RT), or chemotherapy are widely acknowledged to result in inferior oncologic and survival outcomes when compared to RC \[[@ref007]\]. However, trimodal therapy (TMT), consisting of complete TURBT, chemotherapy, and RT has demonstrated durable oncologic control and long-term survival in a number of studies, including two phase 3 randomized controlled trials (RCT) and a large pooled analysis \[[@ref014]\]. TMT represents the most widely studied approach to bladder preservation, and its utilization has gained broader acceptance. Existing TMT series have identified a number of prognostic factors associated with long-term oncologic outcomes, with completion of maximal TURBT consistently representing the strongest predictor of success \[[@ref016]\]. It is important to note, however, that complete TURBT represents a subjective procedural assessment that is not amenable to control between providers or published series. The review presented here provides a detailed description of the role of TURBT in trimodal therapy and subsequent follow-up.

TRIMODAL THERAPY AS A TREATMENT MODALITY FOR MIBC {#sec0010}
=================================================

Treatment Strategies {#sec0015}
--------------------

There are two approaches to TMT that have been described in the literature; *split-course* ([Fig. 1](#blc-2-blc160076-g001){ref-type="fig"}) and *continuous-course* regimens ([Fig. 2](#blc-2-blc160076-g002){ref-type="fig"}). The split course approach was developed through theRadiation Therapy Oncology Group (RTOG) and consists of maximal TURBT followed by induction RT with concurrent chemotherapy and mid-course re-staging TURBT/biopsy. Presence of invasive disease (T1 or greater) on this re-staging procedure necessitates immediate RC if cure is the intent. Those determined to have a complete response or recurrence limited to superficial (Ta or Tis) disease are then treated with a course of consolidation chemo- and radiation therapy (chemo-RT) and followed with regular interval cystoscopy. Following consolidation chemo-RT, subsequent non-muscle invasive bladder cancer (NMIBC) recurrences are managed similarly to those with newly diagnosed NMIBC, with complete repeat TURBT with or without intravesical therapy. The largest institutional experience with split-course TMT comes out of the Massachusetts General Hospital (MGH), with numerous published series representative of distinct RTOG treatment protocols \[[@ref019]\].

In continuous-course regimens, maximal TURBT is followed by chemo-RT and restaging TURBT/biopsy is delayed until 1-3 months following completion of chemo-RT regimens, allowing for adequate time for clinical response. Those determined to have a complete response based on a negative re-staging TURBT/biopsy are placed into a surveillance arm and are followed with regular interval cystoscopy. Again, patients with recurrent NMIBC are managed with repeat TURBT with or without intravesical therapy followed by interval surveillance cystoscopy. Recurrence of MIBC at any point is managed with salvage RC. This treatment approach has been validated by a number of long-term institutional series and prospective studies and represents an increasingly utilized TMT approach \[[@ref014]\]. Currently no prospective studies exist comparing split and continuous regimens, and utilization is generally determined by institutional preference and experience. Additionally, the use of intravesical therapies, including Mitomycin C, Valrubicin, and BCG in conjunction with TMT has not yet been investigated. Any utilization of these agents would be based on evidence extrapolated from non-TMT series, and there is currently no defined role for intravesical therapy in the setting of TMT. A detailed summary of currently available continuous and split course TMT series is provided in [Table 1](#blc-2-blc160076-t001){ref-type="table"}.

Impact of TURBT on TMT Response {#sec0020}
-------------------------------

TMT is primarily employed for patients with good performance status and who elect to attempt bladder preservation with RC implemented only as a salvage option. Predictors of treatment response remain a critical need, however, as TMT non-responders have a 20--40% lower 5-year cancer specific survival (CSS) following salvage RC compared to those undergoing immediate RC \[[@ref016]\]. That being said, maximal TURBT (visually complete resection of the tumor) is the strongest predictor of both oncologic control and TMT success, with a documented 20% increase in complete response and long-term bladder preservation in those receiving complete TURBT \[[@ref019]\]. The therapeutic benefit of TURBT is likely secondary to the direct resection of all readily identifiable muscle-invasive disease but also may be a surrogate for disease aggressiveness. While, the presence of previously unidentified tumor on restaging TURBT signifies disease that is more likely to fail TMT, the ability to perform a complete re-resection allows for optimization of RT, thus increasing the likelihood of TMT success within this subset of patients. Of note, the absence of maximal TURBT was an exclusion criteria for several TMT series, further signifying the importance of this factor \[[@ref031]\].

In addition to incomplete TURBT, several other variables predictive of poor therapeutic response have been identified. Hydronephrosis has been an exclusion criteria for RTOG protocols since 1993, as patients without evidence of ureteral obstruction have demonstrated a response rate≥1.5 times that of patients with hydronephrosis \[[@ref024]\]. Multifocality, while not shown to be significantly associated with response rates or survival, has been associated with higher risk for local relapse and generally represents an exclusion criteria for all previous TMT trials, and bladder preservation is generally not recommended in this population \[[@ref028]\]. Previous series of RT monotherapy also demonstrated poor response rates in patients with T4 disease and CIS, and given that RT represents an integral component of TMT, it has been the general consensus that these patients remain poor candidates even with a multi-modal approach \[[@ref036]\]. Additionally, high-risk histologic features associated with decreased overall therapeutic success following RC, including LVI, variant histology, and tumor grade, are likely prognostic in TMT \[[@ref037]\].

TECHNIQUES FOR PERFORMING MAXIMAL TRANSURETHERAL RESECTION {#sec0025}
==========================================================

Transurethral resection of bladder tumor (TURBT) is one of the most commonly performed urologic procedures, and it is essential for adequately diagnosing and treating bladder tumors. Multiple established guidelines for both NMIBC and MIBC emphasize the importance of ensuring complete resection of all visible tumors and including detrusor muscle in the resection specimen \[[@ref039]\]. Complete resection is associated with lower recurrence rates following initial TURBT in patients with non-muscle-invasive disease, and it is associated with improved long term oncologic outcomes in patients undergoing TMT. Despite these recommendations, multiple studies have reported residual cancer in 30--70% of patients on repeat TURBT \[[@ref045]\]. Surgical technique, operator experience, and tumor size/location have all been shown to impact the quality and completeness of resection \[[@ref047]\]. There are a number of key preoperative and intraoperative factors that should be considered in order to optimize TURBT outcomes.

Preoperative considerations {#sec0030}
---------------------------

Key aspects of the patient history include tobacco use, prior history of bladder cancer, previous endoscopic surgical management, and history of intravesical therapy. During office-based cystoscopy, the exact location, size, number and appearance of the tumor or tumors should be well-documented. Photos or schematic diagrams may be uploaded into the electronic medical record to help document these findings. Preparation for surgery should include routine laboratory evaluation, typically a hematocrit/hemoglobin, electrolytes, and creatinine, as well as a urinalysis or urine culture to evaluate for a urinary tract infection.

There are also key anesthetic considerations that should be addressed in advance of TURBT. General anesthesia with complete neuromuscular blockade is often recommended, as it decreases the likelihood of an obturator reflex and subsequent bladder perforation during TURBT. Alternatively, spinal anesthesia can be utilized and allows for maximal paralysis and bladder relaxation during the surgicalprocedure with a documented 96% successful obturator reflex inhibition rate in one series \[[@ref049]\]. Transurethral or ultrasound-guided injection of the obturator nerve has also been reported to be an effective method of adductor and obturator reflex blockade, and could be considered in patients in whom systemic neuromuscular blockade may be contraindicated \[[@ref049]\]. According to the *AUA Best Practice Policy Statement on urologic surgery antimicrobial prophylaxis*, patients should receive antimicrobial prophylaxis with a fluoroquinolone or sulfamethoxazole-trimethoprim. Alternatively, a 1st/2nd generation cephalosporin, aminoglycoside with or without ampicillin or amoxicillin/clavulanate may be used \[[@ref051]\].

Intraoperative considerations {#sec0035}
-----------------------------

To begin the procedure, a systematic approach is critical and begins with a thorough pancystoscopy. This should be completed with the bladder volume maintained at approximately half-capacity in order to avoid over-distension and improve visualization. Again, the exact location of all identified tumors should be documented in order to facilitate appropriate surveillance, especially in lesions located in areas that may be difficult to visualize \[[@ref052]\].

While small papillary lesions may be removed with either cold cup biopsy forceps or loop electrocautery, larger bladder tumors should be removed systematically with the loop electrocautery. An advantage of the cold cup biopsy technique for small lesions is the avoidance of cautery artifact, improving the pathologist's ability to analyze the specimen. When using electrocautery, either a monopolar or bipolar generator may be utilized, as these have been shown to be equally effective and safe \[[@ref053]\]. While *TUR syndrome* from absorption of hypotonic solutions is more commonly associated with prostate resection for benign prostatic hyperplasia, it can rarely occur following TURBT of large bladder tumors. Bipolar technology allows for the use of nonconductive isotonic irrigation fluids, substantially diminishing the risk of TUR syndrome. Furthermore, by using reduced power settings with bipolar instruments, the risk of triggering an obturator reflex can be decreased without a  compromise in procedural efficacy.

TURBT of large bladder tumors can be a challenging procedure, and adherence to key principles is critical in order to provide optimal staging and maximize the chances for complete resection while maintaining patient safety. Great care needs to be taken to visualize the normal urothelium adjacent to the tumor in order to avoid perforation, and certainly the risk of complications, including perforation and post-operative hematuria, is greater with more extensive resections. Whenever feasible, resection should be initiated at the tumor edge, carried down to the detrusor muscle, and then carried systematically across the tumor. Resection of the detrusor muscle is imperative, and care should be taken to limit cautery artifact during resection \[[@ref055]\]. When resecting large tumors, a separate specimen from the deep margin of resection containing muscularis propria should be included to facilitate accurate pathologic staging \[[@ref052]\]. Very large tumors should be resected piecemeal prior to resecting the stalk of the tumor in order to avoid difficulties evacuating the tumor pieces from the resectoscope. If resection of the ureteral orifice is required, coagulation current around the orifice should be avoided, and it should be carefully examined at the end of the procedure to ensure efflux of urine.

RECENT ADVANCES {#sec0040}
===============

Hexyl-aminolevulinate blue light cystoscopy (HAL-BLC) {#sec0045}
-----------------------------------------------------

HAL-BLC has in recent years emerged as an important adjunct to white-light cystoscopy (WLC), to improve completeness and quality of resection \[[@ref056]\]. HAL-BLC facilitates detection of additional lesions compared to WLC and is associated with reduced rates of recurrence \[[@ref057]\]. HAL-BLC works through the photodynamic property of hexaminolevulinate (HAL) (Hexvix^®^, Cysview^®^, Photocure^®^), which is preferentially taken up by neoplastic cells. HAL was approved by the United States Food and Drug Administration (FDA) in 2010 to be used as an adjunct to WLC for the detection of NMIBC in select patients with known lesions identified on prior cystoscopy. 5-aminolevulinic acid (5-ALA) is another well-investigated compound with photodynamic properties, but which has not yet been approved by the FDA for routine clinical use. \[[@ref059]\]

A large body of evidence supports the utility of HAL-BLC at the time of TURBT. Burger and colleagues demonstrated in a large meta-analysis of over 1,345 patients with NMIBC that the use of HAL-BLC as an adjunct to WLC significantly improved the detection rate of Ta tumors (14.7% absolute increase, *p* \< 0.001) and CIS (40.8% absolute increase, *p* \< 0.001) \[[@ref058]\]. Additionally, using HAL and blue light cystoscopy led to a  statistically significant reduction in recurrence rates up to 12 months after resection (34.5% vs 45.4%; *P* = 0.006). Patients undergoing HAL blue light cystoscopy receive 50 ml of reconstituted solution instilled into an empty bladder via urethral catheter one hour prior to TURBT \[[@ref047]\]. While the utilization of this technology has not been specifically studied in the setting of TMT, its incorporation could result in improved recognition of tumor multifocality and CIS, facilitating both complete resection and improved patient selection for TMT.

TRANSURETHRAL RESECTION AS A COMPONENT OF TMT {#sec0050}
=============================================

Completion of maximal debulking TURBT represents an important prognostic factor in patients undergoing TMT, yet its actual impact on survival is more difficult to assess. As previously discussed, maximal TURBT is associated with a 20% increase in TMT complete response and long-term bladder preservation rates \[[@ref019]\]. The complete resection of all macroscopic elements at primary TURBT results in an optimized environment for chemo-RT to treat residual microscopic components, subsequently resulting in improved initial and long-term response rates. In those patients found to have residual disease at the time of interval TURBT, bladder preservation rates are significantly lower. However, in those receiving split-course regimens with recurrent Ta or Tis disease, repeat TURBT continues to play an important role, as it again allows for optimization of consolidation chemo-RT regimens \[[@ref019]\].

In order to better understand the impact of maximal TURBT as a component of TMT, each treatment modality can be assessed separately. For context, 5-year overall survival (OS) and CSS in patients treated with TMT ranges from 36--74% and 50--82%, respectively \[[@ref016]\]. This range likely stems from varying RTOG protocols, inclusion/exclusion criteria, follow-up durations, and study designs. Pooled analyses of TMT completed under various RTOG protocols have reported 5-year CSS of 60--65% \[[@ref019]\].

There is a relative paucity of literature describing TURBT monotherapy for MIBC; however, durable bladder preservation has been reported in highly selected patients with small MIBC tumors. In one retrospective series, patients found to have no MIBC at repeat TURBT demonstrated a bladder preservation and overall survival rate of 57% and 76%, respectively \[[@ref008]\]. In another prospective series, Solsona and colleagues reported a 10-year CSS rate of 80% and 10-year progression free survival (PFS) rate of 65% \[[@ref009]\]. Strict inclusion criteria were used in these studies, with only 11--35% of patients found to be eligible for definitive TURBT \[[@ref008]\]. Additionally, tumor recurrence and salvage cystectomy rates among this subset of patients is as high as 56% and 30%, respectively \[[@ref008]\]. The role of TURBT monotherapy in MIBC is thus limited, however its potential to effectively cure MIBC in a subset of patients is indicative of the potential impact of this modality as a  component of TMT.

While RT alone was formerly utilized in the management of MIBC, isolated RT results in inferior 5-year OS rates ranging from 26--35% \[[@ref014]\]. RT monotherapy is therefore now restricted to patients deemed unfit for surgery and chemotherapy. There are no data regarding the use of isolated chemotherapy in the management of MIBC, however in bladder preservation regimens, chemo-RT is widely favored over RT alone. Although limited data exists directly comparing these entities, a multicenter, phase 3 trial comparing isolated chemotherapy and chemo-RT for MIBC demonstrated improved 2-year PFS (67% vs. 54%, HR 0.68; *p* = 0.03) and 5-year OS (48% vs. 35%, HR 0.82; *p* = 0.16) rates in patients receiving chemo-RT as compared to RT alone \[[@ref014]\].

While complete TURBT imparts a significant survival benefit, as evidenced by the efficacy of TURBT monotherapy, the ability of chemo-RT regimens to further reduce disease burden through the elimination of residual microscopic disease is a key component of TMT regimens and is indicative of the interdependence of these treatment modalities.

THE ROLE OF NEOADJUVANT CHEMOTHERAPY PRIOR TO TURBT IN TMT {#sec0055}
==========================================================

While the oncologic benefit of neoadjuvant chemotherapy prior to RC in patients with MIBC is clear, this relationship may not hold true for patients undergoing bladder preservation with TMT. Several prospective and retrospective studies have investigated the efficacy of neoadjuvant chemotherapy in the setting of TMT. RTOG 89-03 represents the first large randomized trial directly comparing a standard TMT protocol with and without neoadjuvant cisplatin, methotrexate, and vinblastine (CMV) \[[@ref061]\]. This study was terminated early due to high rates of severe toxicities, with only 64% of included patients completing their specified treatment regimen. Additionally, no significant difference was noted in complete response, metastasis-free survival, or overall survival between the two study arms. Several other series have also reported an increased incidence of adverse events associated with neoadjuvant cisplatin-based chemotherapy regimens, with overall completion rates ranging from 68--93% \[[@ref025]\]. In agreement with these series, a review of the MGH institutional experience also failed to demonstrate a survival benefit associated with neoadjuvant chemotherapy in the setting of TMT \[[@ref019]\].

THE ROLE OF TURBT IN TMT SURVEILLANCE {#sec0060}
=====================================

Following completion of TMT, surveillance is crucial in light of the high recurrence risk. A standardized follow-up regimen does not currently exist for TMT responders, and surveillance protocols are widely provider dependent. The general recommendation from those with longstanding experience with TMT is for vigilant follow-up with cystoscopy and cross-sectional imaging consisting of CT or MRI, with immediate salvage RC offered at the first sign of invasive disease recurrence. There is no consensus as to the frequency of post-TMT surveillance cystoscopy, however many providers follow standard high-risk NMIBC protocols with cystoscopy performed approximately every 3 months for the first 2 years, every 6 months for the next 2 years, and annually thereafter. Urine cytology should be collected with each cystoscopic evaluation and GU imaging should be performed annually.

The majority of TMT trials also advocate for repeat biopsy or re-resection of the original TURBT resection site at first surveillance cystoscopy, which is routinely completed 8--12 weeks following the completion of chemo-RT. Routine cold-cup biopsy at interval follow-up is not necessary but may be performed as deemed appropriate. Additionally, some recommend routine bi-manual examination due to the potential for MIBC recurrence deep to the original TURBT scar. Given the subjective nature of cystoscopy and lack of standardized documentation of precise examination findings, the urologist performing the original TURBT for TMT should ideally perform interval follow-up cystoscopies as well. The majority of TMT trials with a long duration of follow-up describe a  flattening of the CSS curve at 5 years, similar to that observed with standard RC, and indicating long-term durability for patients who respond to TMT \[[@ref019]\]. Late recurrences can occur, however, and thus life-long surveillance cystoscopy is recommended in all patients undergoing TMT \[[@ref064]\].

THE ROLE OF TURBT IN THE MANAGEMENT OF DISEASE RECURRENCE FOLLOWING TMT {#sec0065}
=======================================================================

NMIBC recurrence {#sec0070}
----------------

Bladder cancer recurrence in patients who experience an initial complete response to TMT varies from 24--43%, with the majority of reported series demonstrating a median time to local recurrence of \<2 years \[[@ref024]\]. Patients experiencing Ta NMIBC recurrence may be managed with repeat TURBT \[[@ref024]\]. Institution of intravesical BCG may provide further therapeutic benefit, however, the efficacy of this modality in the setting of TMT recurrence is not well defined \[[@ref024]\]. Patients with T1 recurrence should be strongly considered for salvage cystectomy, although TURBT and intravesical BCG remains an option. Future Ta recurrences can be managed with repeat TURBT, while salvage RC may be necessary in those cases in which TURBT is not felt to be an appropriate option secondary to high burden of disease, difficult tumor location, or recurrent high-risk NMIBC. Patients experiencing NMIBC recurrence have a significantly increased risk of future TMT failure, and 19--45% of these patients will eventually require salvage RC \[[@ref008]\]. While patients with NMIBC recurrence are more likely to eventually require salvage RC, they appear to have a CSS similar to those without NMIBC recurrence \[[@ref066]\].

MIBC recurrence and treatment failure {#sec0075}
-------------------------------------

Following complete response to TMT, evidence of recurrent MIBC at any point constitutes TMT failure and necessitates immediate salvage RC in all patients deemed medically fit to undergo operative intervention. Of those who experience recurrence of disease, 11--19% will be found to have MIBC \[[@ref014]\]. Despite a delay to surgical treatment, TMT complete responders receiving salvage RC have demonstrated 5-year post-RC CSS rates similar to those undergoing primary RC \[[@ref028]\]. Overall rates of salvage RC, consisting of both immediate non-responders and initial complete responders ranges from 25--30% \[[@ref014]\]. There is typically no role for TURBT in the management of MIBC recurrence with curative intent.

QUALITY OF LIFE CONSIDERATIONS {#sec0080}
==============================

An improved overall quality of life represents an assumed benefit and primary driving force for many patients electing to undergo bladder preservation therapy with TMT. Despite the morbidity associated with RC, multiple studies using several different validated instruments have shown good overall health-related quality of life following surgery regardless of the type of urinary diversion chosen \[[@ref079]\]. However, both urinary incontinence and erectile dysfunction can be significant post-operative issues. Gilbert et al reported that 54% of patients undergoing RC with neobladder experienced nightly urinary leakage, and the impact of incontinence on quality of life for those undergoing RC with neobladder diversion was significantly greater than controls not treated with RC \[[@ref080]\]. Additionally, sexual function was noted to be significantly lower and more bothersome in both RC groups (neobladder and ileal conduit) when compared to non-operative controls.

Data pertaining to quality of life and bladder function following TMT is currently limited. In one analysis of 32 long-term TMT survivors, urodynamics revealed no abnormalities in 24 patients (75%) and decreased compliance in 7 patients (22%) \[[@ref085]\]. Urinary complaints included symptoms of abnormal flow (6%), urinary urgency (15%), and incontinence (19%); however, distress from these symptoms was only half as common as their prevalence. In terms of sexual function, 54% of men were capable of achieving an erection satisfactory for sexual intercourse and only 8% reported dissatisfaction with their sexual function. While overall global health-related quality of life was high amongst this cohort, no direct comparison of TMT and RC has been performedto date.

CONCLUSIONS {#sec0085}
===========

TMT is a viable alternative to RC in select patients with MIBC who desire bladder preservation or cannot tolerate major surgery. Careful selection of patients with a unifocal tumor and absence of hydronephrosis or adverse pathologic features offer the best chance for a durable response. Performing a complete TURBT as part of TMT is paramount to maximizing cancer control and long-term bladder preservation rates. Additionally, TURBT plays a  critical role in assessing TMT response and in the management of NMIBC recurrences while on TMT protocols. Advances in tumor profiling, predictive biomarkers, dosing, delivery of radiation therapy, and use of systemic immunotherapy may continue to expand the pool of patients eligible for TMT and further improve outcomes.

DISCLOSURES {#sec0090}
===========

None.

![Pictographic representation of split-course trimodal therapy regimen.](blc-2-blc160076-g001){#blc-2-blc160076-g001}
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Summary of published continuous and split course TMT series

                                          Study Design                                              Split/       Follow-up   *N*   Chemotherapy                                         RT Dose                Neoadjuvant/                                      Complete  Salvage   CSS             OS
  --------------------------------------- --------------------------------------------------------- ------------ ----------- ----- ------------------------------------- ------------------------------------- ------------------------------------------------ ---------- --------- --------------- ----------------
  James et al., 2012 \[[@ref014]\]        Prospective, Phase III                                    Continuous   69.9        182   5-FU and Mitomycin C×2                             55 or 64 Gy              --                                                   --     11.4%     --              48% (5 yr)
  Tunio et al., 2012 \[[@ref015]\]        Prospective Phase III                                     Continuous   60.0        200   Cisplatin \[Weekly\]                                  65 Gy                 --                                                  93%     --        --              52% (5 yr)
  Zapatero et al., 2012 \[[@ref031]\]     Retrospective                                             Split        60.0        39    Cisplatin (Paclitaxel: *n* = 5)                      64.8 Gy                --                                                  80%     33%       82% (5 yr)      73% (5 yr)
  Efstathiou et al., 2012 \[[@ref019]\]   Retrospective                                             Split        92.4        348   Various                                              Various                Various Neoadjuvant and Adjuvant Regimens           78%     29%       5 yr -- 64%     5 yr -- 52%
                                                                                                                                                                                                                                                                                     10 yr -- 59%    10 yr -- 35%
                                                                                                                                                                                                                                                                                     15 yr -- 57%    15 yr -- 22%
  Lagrange et al., 2011 \[[@ref073]\]     Prospective Phase II                                      Split        96.0        51    Cisplatin and 5-FU×3                                  63 Gy                 --                                                   --     33.3%     --              8 yr -- 36%
  Choudhury et al., 2011 \[[@ref072]\]    Prospective Phase II                                      Continuous   36.0        50    Gemcitabine \[Weekly\]                               52.5 Gy                --                                                  82%     14%       3 yr -- 82%     3 yr -- 75%
                                                                                                                                                                                                                                                                                     5 yr -- 78%     5 yr -- 65%
  Krause et al., 2011 \[[@ref030]\]       Retrospective                                             Split        71.5        473   Various                                   Various (RT only: *n* = 126)      --                                                 70.4%    --        --              5 yr -- 49%
                                                                                                                                                                                                                                                                                                     10 yr -- 30%
  Sabaa et al., 2010 \[[@ref022]\]        Retrospective                                             Split        47.0        104   Cisplatin×2                                         60--65 Gy               Neoadjuvant Gemcitabine and Cisplatin×3            78.8%    16.7%     5 yr -- 76%     5 yr -- 68%
  Aboziada et al., 2009 \[[@ref074]\]     Retrospective                                             Split        18.0        50    Cisplatin \[Weekly\]                                  66 Gy                 --                                                  60%     28%       1.5 yr -- 84%   1.5 yr -- 100%
  Kaufman et al., 2009 \[[@ref069]\]      Prospective Phase *I* + II                                Split        49.4        80    Cisplatin \[Weekly\] + Paclitaxel×5                  64.3 Gy                AdjuvantCisplatin and Gemcitabine×4                 81%     12.5%     5 yr -- 71%     5 yr -- 56%
  Perdona et al., 2008 \[[@ref021]\]      Retrospective                                             Continuous   66.0        78    Cisplatin (Carboplatin: *n* = 25)                     65 Gy                 Neoadjuvant CMV×2                                  85.7%    20.2%     5 yr -- 79%     5 yr -- 72%
  Weiss et al., 2007 \[[@ref065]\]        Retrospective                                             Continuous   27.0        112   Cisplatin and 5-FU×2                              55.8--59.4 Gy             --                                                  88%     17%       5 yr -- 82%     5 yr -- 74%
  Gogna et al., 2006 \[[@ref070]\]        Prospective Phase II                                      Continuous   23.0        113   Cisplatin \[Weekly\]                                63--64 Gy               --                                                  70%     15%       5 yr -- 50%     
  Cobo et al., 2006 \[[@ref027]\]         Retrospective                                             Split        69.4        29    Cisplatin×2                                          64.8 Gy                Neoadjuvant CMV×2 or Gemcitabine and Cisplatin      86%     24.1%     --              6 yr -- 72%
  Kragelj et al., 2005 \[[@ref061]\]      Prospective Phase II                                      Continuous   123.6       84    Vinblastine \[Weekly\]                             63.8--64 Gy              --                                                  78%     8.3%      9 yr -- 51%     9 yr -- 25%
  Peyromaure et al., 2004 \[[@ref032]\]   Retrospective                                             Split        36.3        43    Cisplatin and 5-FU×2                                  24 Gy                 --                                                 74.4%    25.6%     3 yr -- 75%     --
                                                                                                                                                                                                                                                                                                     5 yr -- 60%
  Hussain et al., 2004 \[[@ref077]\]      Prospective Phase *I* + II                                Continuous   50.7        41    Mitomycin C and 5 FU×2                                55 Gy                 --                                                  71%     19.5%     2 yr -- 68%     2 yr -- 49%
                                                                                                                                                                                                                                                                                                     5 yr -- 36%
  Danesi et al., 2004 \[[@ref020]\]       Retrospective                                             Continuous   82.2        77    Cisplatin and 5-FU                                    69 Gy                 Neoadjuvant CMV×2                                  80.5%    22.1%     5 yr -- 75%     5 yr -- 59%
                                                                                                                                                                                                                                                                                     10 yr -- 73%    10 yr -- 55%
  Hagan et al., 2003 \[[@ref067]\]        Prospective Phase *I* + II                                Split        26.0        47    Cisplatin \[Weekly\]                                 64.8 Gy                Adjuvant CMV×3                                      74%     25.5%     --              3 yr -- 61%
  Rödel et al., 2002 \[[@ref028]\]        Retrospective                                             Continuous   60.0        415   Various                                45 -- 69.4 Gy (RT alone: *n* = 126)  --                                                  72%     20%       5 yr -- 56%     5 yr -- 51%
                                                                                                                                                                                                                                                                                     10 yr -- 42%    10 yr -- 31%
  Kaufman et al., 2000 \[[@ref078]\]      Prospective Phase *I* + II                                Split        29.0        34    Cisplatin and 5-FU×4                                  44 Gy                 --                                                  67%     29.4%     3 yr -- 83%     --
  Arias et al., 2000 \[[@ref023]\]        Retrospective                                             Split        73.0        50    Cisplatin×1                                           65 Gy                 Neoadjuvant M-VAC×2                                 68%     26%       --              5 yr -- 48%
  Shipley et al., 1998 \[[@ref016]\]      Prospective Phase III (Arm 1: No Neoadjuvant Therapy)     Split        60.0        62    Cisplatin×3                                          64.8 Gy                --                                                  60%     25.8%     --              5 yr -- 49%
  Shipley et al., 1998 \[[@ref016]\]      Prospective Phase III (Arm 2: With Neoadjuvant Therapy)   Split        60.0        61    Cisplatin×3                                           64.8                  Neoadjuvant CMV×2                                  72.5%    17%       --              5 yr -- 48%
  Kachnic et al., 1997 \[[@ref024]\]      Retrospective                                             Split        52.8        106   Cisplatin×3                                          64.8 Gy                Neoadjuvant CMV×2                                   80%     21.7%     5 yr -- 60%     5 yr -- 52%
  Fellin et al., 1997 \[[@ref026]\]       Prospective Phase II                                      Split        46.0        56    Cisplatin                                             64 Gy                 Neoadjuvant CMV×2                                   50%     46.4%     5 yr -- 59%     5 yr -- 54%
  Tester et al., 1996 \[[@ref025]\]       Prospective Phase II                                      Split        52.8        91    Cisplatin×3                                          64.8 Gy                Neoadjuvant CMV×2                                   75%     39.5%     --              4 yr -- 62%
  Housset et al., 1993 \[[@ref017]\]      Prospective Phase III                                     Split        27.0        54    Cisplatin and 5-FU×4                                  44 Gy                 --                                                  74%     --        3 yr -- 62%     3 yr -- 59%
  Tester et al., 1993 \[[@ref075]\]       Prospective Phase III                                     Split        36.0        48    Cisplatin×3                                           64 Gy                 --                                                  66%     20.8%     --              3 yr -- 64%
  Russell et al., 1990 \[[@ref076]\]      Prospective Phase II                                      Split        18.0        34    5-FU                                                  60 Gy                 --                                                  81%     29.4%     --              4 yr -- 64%

RT = Radiation Therapy; RC = Radical Cystectomy; CSS = Cancer Specific Survival; OS = Overall Survival; 5-FU = 5-Fluorouracil; CMV = Cisplatin, Vinblastine, Methotrexate; M-VAC = Methotrexate, Cisplatin, Adriamycin, Vinblastine; yr = Year.
